Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 19/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | ATRIP | Q8WXE1 | 6/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049918 | 0.78 | PIK3CA (0.56) | ATRATRIPPIK3CAMTORPRKDC | |
| SCHEMBL4377456 | 0.77 | CSNK1D (0.32) | — | |
| SCHEMBL24812436 | 0.65 | ATR (0.56) | ATRBRAFATRIP | |
| SCHEMBL4055681 | 0.64 | PIK3CA (0.59) | ATRPIK3R1PIK3CAMTORPRKDC | |
| SCHEMBL21263052 | 0.62 | ATR (0.75) | ATRATRIPPIK3R1PIK3CAMTOR | |
| SCHEMBL21263177 | 0.62 | ATR (0.75) | ATRATRIPPIK3R1PIK3CAMTOR | |
| SCHEMBL20798255 | 0.61 | ATR (0.73) | ATRATRIPPIK3R1PIK3CAMTOR | |
| SCHEMBL30629304 | 0.61 | ATR (0.73) | ATRATRIPPIK3R1PIK3CAMTOR | |
| SCHEMBL24811619 | 0.61 | ATR (0.70) | ATRBRAFATRIP | |
| SCHEMBL7907534 | 0.61 | ATR (0.80) | ATRATRIPPIK3R1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009111547-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | claimed |
| WO-2009111547-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-11 | — | — | WO | disclosed |
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227575-A1 | 7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS | MTOR, RICTOR, RPS6KA3 | ATR 538/4885BRAF 155/4885ATRIP 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.